Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arbutus Biopharma

3.13
-0.0700-2.19%
Volume:593.24K
Turnover:1.88M
Market Cap:599.48M
PE:-7.68
High:3.22
Open:3.19
Low:3.13
Close:3.20
Loading ...

Arbutus Biopharma Reacquires Rights to Imdusiran in China

MT Newswires Live
·
25 Jun

BRIEF-Arbutus Reacquires Greater China Rights to Imdusiran

Reuters
·
25 Jun

Arbutus Biopharma Corp. Announces New Scientific Advisory Board with Focus on Late-Stage Clinical Trials

Reuters
·
25 Jun

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board With Late-Stage Clinical Focus

THOMSON REUTERS
·
25 Jun

Arbutus Biopharma Holds Annual Shareholder Meeting

TIPRANKS
·
24 May

Arbutus Biopharma Corp. Conducted Annual Shareholder Meeting

Reuters
·
24 May

Arbutus Biopharma Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Arbutus Biopharma reports Q1 EPS (13c), consensus (15c)

TIPRANKS
·
14 May

Arbutus Biopharma Q1 EPS $(0.13) Misses $(0.10) Estimate, Sales $1.76M Miss $1.78M Estimate

Benzinga
·
14 May

BRIEF-Arbutus Biopharma Q1 Revenue USD 1.8 Million Vs. IBES Estimate USD 1.78 Million

Reuters
·
14 May

Arbutus Biopharma Q1 2025: Revenue Up 20% to $1.8M, Net Loss Widens to $24.5M, EPS at $(0.13)

Reuters
·
14 May

Arbutus Biopharma Corp - Reports $12.4 Mln in Restructuring Costs for Q1 2025

THOMSON REUTERS
·
14 May

Arbutus Biopharma Q1 Revenue USD 1.8 Million VS. Ibes Estimate USD 1.78 Million

THOMSON REUTERS
·
14 May

Arbutus Biopharma Q1 Net Income USD -24.5 Million

THOMSON REUTERS
·
14 May

Arbutus Presents Clinical Trial Data From Its Two Hbv Assets, Imdusiran and Ab-101, at the European Association for the Study of the Liver (Easl) Congress 2025

THOMSON REUTERS
·
07 May

GE HealthCare to feature latest advancements in diagnostic accuracy and patient-centered breast care at SBI 2025 Breast Cancer Imaging Symposium

Business Wire
·
25 Apr

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know

Zacks
·
24 Apr

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

GlobeNewswire
·
23 Apr

Arbutus Biopharma Down Over 8%, on Pace for Largest Percent Decrease Since April 2023 -- Data Talk

Dow Jones
·
07 Apr

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Zacks
·
01 Apr